ABSTRACT

Disclosed is a pharmaceutical combination comprising a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotope labeled analogue thereof, a crystalline form thereof, a hydrate, a solvate, a diastereomeric or enantiomeric form thereof, and a DPP-IV inhibitor. Disclosed are a pharmaceutical composition and a fixed dose combination formulation, and the methods for preparing the pharmaceutical composition and the fixed dose combination formulation and the uses thereof.